Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAX NASDAQ:NKTX NASDAQ:PGEN NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$12.00+0.8%$10.74$7.80▼$28.09$654.72MN/A583,828 shs289,451 shsNKTXNkarta$2.10$2.02$1.31▼$6.63$149.16M0.76922,644 shs422,708 shsPGENPrecigen$4.75-0.2%$2.29$0.65▼$5.23$1.42B1.823.90 million shs9.36 million shsVALNValneva$8.77+1.6%$7.85$3.62▼$12.25$746.24M1.7971,487 shs130,301 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics-0.34%-1.16%+13.01%+6.63%+1,189,999,900.00%NKTXNkarta-0.94%-4.98%-0.94%+11.11%-60.45%PGENPrecigen+5.54%+11.74%+185.03%+257.89%+332.73%VALNValneva-2.49%-3.68%+19.53%+38.08%+17.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANKTXNkarta1.9567 of 5 stars3.50.00.00.02.71.70.6PGENPrecigen4.2827 of 5 stars3.41.00.04.73.23.30.6VALNValneva1.9794 of 5 stars3.53.00.00.01.80.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 3.00Buy$32.25168.76% UpsideNKTXNkarta 3.00Buy$13.60547.62% UpsidePGENPrecigen 2.80Moderate Buy$8.2573.68% UpsideVALNValneva 3.00Buy$15.3374.84% UpsideCurrent Analyst Ratings BreakdownLatest NKTX, VALN, BCAX, and PGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025VALNValnevaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$14.008/25/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/22/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.008/19/2025PGENPrecigenCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform8/19/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.008/19/2025PGENPrecigenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.508/19/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.008/18/2025BCAXBicara TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$36.008/15/2025PGENPrecigenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Neutral8/14/2025NKTXNkartaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.008/13/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/A$7.98 per shareN/ANKTXNkartaN/AN/AN/AN/A$5.04 per shareN/APGENPrecigen$3.92M361.06N/AN/A($0.12) per share-39.58VALNValneva$183.52M4.07$0.10 per share90.57$2.49 per share3.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara Therapeutics-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)NKTXNkarta-$108.79M-$1.48N/AN/AN/AN/A-27.74%-22.38%11/6/2025 (Estimated)PGENPrecigen-$126.24M-$0.42N/AN/AN/A-2,868.66%-842.83%-78.98%11/13/2025 (Estimated)VALNValneva-$13.25M-$0.98N/AN/AN/A-33.87%-34.78%-13.43%11/6/2025 (Estimated)Latest NKTX, VALN, BCAX, and PGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54-$0.50+$0.04-$0.50N/AN/A8/12/2025Q2 2025NKTXNkarta-$0.37-$0.31+$0.06-$0.31N/AN/A8/12/2025Q2 2025PGENPrecigen-$0.14-$0.11+$0.03-$0.09$0.67 million$0.86 million8/12/2025Q2 2025VALNValneva-$0.27-$0.16+$0.11-$0.16$46.28 million$54.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/A25.8025.80NKTXNkartaN/A15.6715.67PGENPrecigenN/A2.712.71VALNValneva0.662.271.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/ANKTXNkarta80.54%PGENPrecigen33.51%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipBCAXBicara TherapeuticsN/ANKTXNkarta8.40%PGENPrecigen47.10%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3254.56 millionN/AN/ANKTXNkarta14071.03 million65.06 millionOptionablePGENPrecigen190297.97 million157.63 millionOptionableVALNValneva70085.09 million72.41 millionNot OptionableNKTX, VALN, BCAX, and PGEN HeadlinesRecent News About These CompaniesValneva Reports Positive Phase 2 Results for Lyme Disease VaccineSeptember 3 at 12:54 PM | msn.comPfizer, Valneva boosted by updated vaccine data ahead of moment in the Lyme-lightSeptember 3 at 12:54 PM | fiercebiotech.comFValneva Shares Rise on Lyme Disease Vaccine Study DataSeptember 3 at 7:54 AM | marketwatch.comValneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine CandidateSeptember 3 at 2:00 AM | globenewswire.comChikungunya: Ixciq, the first authorized vaccine against the virus, under scrutinySeptember 2 at 11:20 PM | lemonde.frLFDA License Suspension Ends Use of Chikungunya Vaccine Ixchiq in USAugust 29, 2025 | infectiousdiseaseadvisor.comIHC Wainwright Reiterates "Buy" Rating for Valneva (NASDAQ:VALN)August 27, 2025 | marketbeat.comValneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?August 27, 2025 | marketbeat.comFDA Suspends Valneva Vaccine’s License Following New Reports of Adverse EventsAugust 27, 2025 | medcitynews.comMValneva has biologics license withdrawn for chikungunya vaccineAugust 27, 2025 | thepharmaletter.comTAs Chikungunya Spreads Worldwide, FDA Halts Use of Only U.S.-Approved VaccineAugust 26, 2025 | managedhealthcareexecutive.comMValneva Outlook: Safety Blow To Ixchiq And Valuation ConcernsAugust 26, 2025 | seekingalpha.comValneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The ImpactAugust 26, 2025 | msn.comFDA: Valneva’s Ixchiq unpicked for safety in chikungunyaAugust 25, 2025 | bioworld.comBUS suspends chikungunya vaccine Ixchiq over 'serious' side effects: ValnevaAugust 25, 2025 | e.vnexpress.netEFDA Suspends U.S. License of Chikungunya VaccineAugust 25, 2025 | purdueexponent.orgPValneva stock tumbles as FDA suspends license for IXCHIQ vaccineAugust 25, 2025 | za.investing.comValneva Shares Tumble After Chikungunya Vaccine License Suspended in U.S.August 25, 2025 | marketwatch.comFDA does a 180, suspending use of Valneva's chikungunya vaccineAugust 25, 2025 | fiercepharma.comFSafety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In USAugust 25, 2025 | benzinga.comFDA suspends license for Valneva’s chikungunya shotAugust 25, 2025 | biopharmadive.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNKTX, VALN, BCAX, and PGEN Company DescriptionsBicara Therapeutics NASDAQ:BCAX$12.00 +0.10 (+0.84%) Closing price 04:00 PM EasternExtended Trading$11.70 -0.30 (-2.46%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Nkarta NASDAQ:NKTX$2.10 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.14 +0.04 (+2.14%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Precigen NASDAQ:PGEN$4.75 -0.01 (-0.21%) Closing price 04:00 PM EasternExtended Trading$4.78 +0.03 (+0.53%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Valneva NASDAQ:VALN$8.77 +0.14 (+1.62%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
